From fitness gadget to clinical trial instrument
Galaxy Watch clinical trials are drug studies that use wearable biometric data from Samsung’s smartwatches to turn everyday health signals into regulated digital health endpoints for evaluating new medicines. That shift matters because it pushes consumer wearables out of the wellness niche and directly into pharmaceutical research wearables, where data must stand up in front of regulators and ethics boards. Samsung has announced that it will use biometric data collected through Galaxy Watch devices in clinical trials for new drug development, under a new partnership with digital clinical trial firm Alcedis. This is not a side project; it is a deliberate move to turn a popular smartwatch into infrastructure for evidence generation. If successful, it could change what “going to a trial site” even means, replacing some clinic visits with your wrist.
Why continuous wearable biometric data is a big deal
Traditional trials are built around snapshots: short clinic visits, periodic lab tests, and patient diaries. Wearable biometric data blows that model open by watching what happens between visits, during real life. Samsung’s research platform starts with Galaxy Watch biosensors collecting physiological data from consented users in real-world environments, including measures such as bioelectrical impedance analysis and electrodermal activity. Instead of guessing how patients behave at home, researchers can see it. If this approach works, trial operators could monitor participants more continuously, reduce some reliance on scheduled clinic visits, and collect data that better reflects daily conditions. That is the real promise: not more numbers for the sake of it, but better signals about how a drug performs in the conditions where people actually live. Anything less would be another fitness-tracker gimmick in a lab coat.
Turning consumer signals into digital health endpoints
The risky but exciting bet is that Galaxy Watch biometrics can become digital health endpoints that regulators, sponsors, and clinicians trust. Under their partnership, Samsung and Alcedis will jointly develop methods to convert biometric data collected by Galaxy Watch sensors in real-world environments into clinical endpoints for evaluating the efficacy and safety of investigational drugs. The companies plan to study how real-world signals from consumer wearables could become validated endpoints or biomarkers for drug safety, efficacy, and patient outcomes. Wearables offer a different model by collecting health signals during everyday life, rather than only in controlled settings. If those signals can be validated, pharmaceutical research wearables could support more patient-centered studies and faster evidence generation, potentially cutting parts of the time and operational cost of trials. But the real test is whether these digital endpoints survive regulatory scrutiny, not whether they look impressive in a demo.
A new bridge between hospitals, patients, and pharma
Samsung has been quietly building the plumbing for this moment, expanding a connected-care ecosystem that links wearable-device health data with healthcare services. It has acquired a platform that connects hospitals with digital healthcare solutions and plans to integrate Galaxy health data with hospital electronic health record systems. The Galaxy Watch now sits at an awkward but powerful intersection: it is both a consumer health tracker and a potential medical data source. According to Samsung’s head of health R&D, the goal is to ensure that data generated in everyday life can contribute to drug-development research and innovations that benefit patients. This is where the device becomes a bridge between casual self-tracking and regulated clinical research. If hospitals, trial sponsors, and patients all plug into the same wearable ecosystem, the idea of a “trial visit” could evolve into a mix of home monitoring, telehealth, and occasional in-person assessments.
Privacy, trust, and what must happen next
The uncomfortable truth is that none of this works without trust. For healthcare IT teams, the question is not whether smartwatches can collect more data, but whether that data can be secured, validated, audited, and integrated into regulated clinical research workflows. Clinical trials need accurate, consistent measurements tied to meaningful outcomes, backed by traceable consent, identity management, device control, and audit trails. Those requirements get more complex when consumer devices enter regulated workflows. If Samsung and Alcedis treat the Galaxy Watch like a clinical instrument—subject to verification, standards, and clear governance—wearable biometric data could make trials less burdensome for participants and more useful for researchers. If they treat it like a flashy gadget, regulators will push back and patients may opt out. The future of Galaxy Watch clinical trials will be decided less by sensors and more by how seriously the ecosystem takes data rights, reliability, and accountability.
